Kashiv BioSciences, LLC
http://www.kashivbiosciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kashiv BioSciences, LLC
Amneal Adds Xolair Rival To Biosimilars Pipeline
Amneal has revealed the latest addition to its biosimilars pipeline, in the form of an omalizumab rival to Xolair developed by Kashiv Biosciences.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Celltrion Leads Xolair Biosimilar Race With US FDA Application
This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.
Alvotech Finds A New Omalizumab Partner In Kashiv
After earlier this year revealing that it had dropped a collaboration with BiosanaPharma on a biosimilar omalizumab rival to Xolair, Alvotech has now announced a fresh licensing deal for development and commercialization of a version from Kashiv BioSciences.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Other Names / Subsidiaries
-
- Adello Biologics, LLC
- Kashiv Pharma, LLC
- TheraProteins
- Therapeutic Proteins International
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice